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Abstract Shorter telomeres have been reported in prema-
ture myocardial infarction (MI) patients. Our work aimed at
confirming the association of shorter telomere with MI in
two case–control studies and in familial hypercholesterol-
emia (FH) patients with coronary heart disease (CHD). The
HIFMECH study compared 598 white male patients
(<60 years) who survived a first MI and 653 age-matched
controls from North and South Europe. Additionally, from
the UK, 413 coronary artery bypass graft (CABG) patients
and two groups of 367 and 94 FH patients, of whom 145
and 17 respectively had premature CHD, were recruited.
Leukocyte telomere length (LTL) was measured using a
real-time polymerase chain reaction-based method. In
HIFMECH, LTL was significantly shorter in subjects from
the North (7.99 kb, SD 4.51) compared to the South
(8.27 kb, SD 4.14; p=0.02) and in cases (7.85 kb, SD 4.01)
compared to controls (8.04 kb, SD 4.46; p=0.04). In the
CABG study, LTL was significantly shorter (6.89 kb, SD
4.14) compared to the HIFMECH UK controls (7.53, SD
5.29; p=0.007). In both samples of FH patients, LTL was
shorter in those with CHD (overall 8.68 kb, SD 4.65)
compared to the non-CHD subjects (9.23 kb, SD 4.83; p=
0.012). Apart from a consistent negative correlation with
age, LTL was not associated across studies with any
measured CHD risk factors. The present data confirms that
subjects with CHD have shorter telomeres than controls and
extends this to those with monogenic and polygenic forms
of CHD.
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Introduction
Coronary heart disease (CHD) and its main complication,
myocardial infarction (MI), are the leading cause of
morbidity and mortality in most industrialised nations
throughout the world. Approximately one in five deaths in
men and one in six deaths in women in UK are caused by
CHD (www.heartstats.org). Coronary artery bypass grafting
(CABG) is a common option for myocardial revasculariza-
tion for suitable patients. While in general CHD has a
multifactorial origin, in some cases it has a monogenic
cause such as familial hypercholesterolemia (FH). FH is an
autosomal co-dominant disorder which leads to high levels
of low-density lipoprotein (LDL)-cholesterol and, if un-
treated, to early CHD [1]. Heterozygous FH has been
estimated to affect about one in 500 of the British
population [2].
Risk of CHD is partly heritable and highly variable
between individuals. It is therefore important to predict
disease and initiate treatment to prevent events inducing
permanent cardiac damage. Since CHD risk is age-related,
there is a need for a marker of biological age in evaluating
the risk for early onset of CHD, and recent studies have
suggested telomere shortening to serve as such [3, 4].
Telomeres are specialised DNA-protein structures at the end
of all chromosomes, which preserve chromosome stability
and integrity. In normal cells, the DNA replication
machinery is unable to completely duplicate the telomeric
DNA, and thus telomeres are shortened after each cell
division (reviewed by [5]). This may be compensated by
the action of the telomerase enzyme in some tissues and/or
at certain state in life (reviewed by [6]). On the other hand,
oxidative stress accelerates telomere shortening in cells [7],
and lowered plasma total antioxidant status correlate with
shorter telomere length in diabetics [8]. Telomere length is
highly variable at birth and decreases with age (reviewed by
[9]). Previous studies have demonstrated an association
between telomere length, health and longevity [10]. Shorter
leukocyte telomeres have been measured in MI cases [11]
and offspring of MI cases [12], type II diabetes [13–15] and
other degenerative disease such as dementia and Alzheimer
disease [16]; in this last study, mean telomere length was
shorter among subjects dying during follow-up than in
those surviving.
In the present study, we examined the association of
mean leukocyte telomere length (LTL) with CHD in three
cohorts of patients: HIFMECH (hypercoagulability and
impaired fibrinolytic function mechanisms predisposing to
MI), CABG and FH. HIFMECH is a European multicenter
case–control study, which has as its aim the identification
of differences in risk markers for MI between subjects
living in the North and the South of Europe [17]. CABG is
a previously described [18] cohort of patients surviving a
first elective CABG surgery. For the first time, LTL is
evaluated in FH patients recruited through lipid clinics in
the UK [2, 19]. Moreover, we evaluated the association of
LTL with environmental and lifestyle risk factors as well as
geographical diversity.
Methods
Study samples
All studies had been designed and carried out according to the
Helsinki declaration and received hospital ethics committee
approval. All patients gave written informed consent.
The HIFMECH study compares male survivors of a first
MI aged <60 years (excluding patients with FH and insulin-
dependent diabetes mellitus) and population-based individ-
uals of the same age and region recruited from four centres
in Europe: Stockholm, Sweden and London, England for
the North and Marseille, France and San Giovanni
Rotondo, Italy representing the South [17]. In all, a total
of 598 post-infarction patients and 653 controls were
included in the study. Patients and control subjects were
examined in parallel in the early morning after an overnight
fast. Post-infarction patients were investigated 3 to 6 months
after the acute event. Blood samples were obtained from the
antecubital vein after an overnight fast, collected into citrate
(3.8% citrate, 0.129 mol/L) and centrifuged at 2,500g for
30 min at 4°C.
The CABG patients were drawn from the coronary artery
surgery inflammation study and are described elsewhere
[18]. Briefly, all patients undergoing elective first time
CABG at the Middlesex Hospital, London, UK, between
October 1999 and September 2000 were invited to
participate. Subjects undergoing additional surgical proce-
dures (such as valvular surgery or aneurysmectomy),
subjects with evidence of a pre-existing inflammatory state
or unstable coronary artery disease and subjects who
suffered potentially confounding infective postoperative
complications or circulatory failure requiring inotropic
support were excluded. Aspirin was omitted routinely
10 days before surgery. Blood samples were drawn
preoperatively. These were centrifuged immediately
(3,500g, 10 min), and plasma and cells were separated
and frozen at −20°C. The CABG group includes 439
people (20% women) having different ethnic origin (83%
Caucasians, 8% Asians, 2% Afro-Caribbean, 2% of other
ethnicity and 5% of unknown origin).
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the first FH sample comprises 410 definite FH adult
patients (47.70% women) recruited from the Simon
Broome (SB) Familial Hyperlipidaemia Register for FH
(FH-SH). Definite FH is defined as total cholesterol
concentration >7.5 mmol/l, or LDL-cholesterol concentra-
tion >4.9 mmol/l, plus tendon xanthomas in the patient or a
first- or second-degree relative [2]. At recruitment, CAD
was documented as described [19] in 104 of the 211 men
and in 55 of the 199 women with mean ages of onset of
43.1 and 46.5 years, respectively. Telomere length was
measured in a second group of 94 FH patients from the
Royal Free Hospital (London) (FH-RF). Mean age was
57.7 years old (SD=14.6), and out of this group, 17 patients
had documented CHD.
Phenotypic variables
Details on lifestyle factors (i.e. smoking, alcohol consump-
tion and physical activity), personal and family medical
history and medication and physiological measurements
(i.e. height, weight and blood pressure) were acquired using
standardised questionnaires and protocols across all sites
and have been described in previous publications [18, 19].
Measurement of telomere length
Leukocyte DNA was extracted by the salting-out method
[12]. LTL was measured using a quantitative polymerase
chain reaction (PCR)-based method [20], as adapted in our
laboratory [12]. The relative telomere length was calculated
as the ratio of telomere repeats to single-copy gene (SCG)
copies (T/S ratio). For each sample, the quantity of
telomere repeats and the quantity of SCG copies were
determined in comparison to a reference sample in a
telomere and a SCG quantitative PCR, respectively. All
PCRs were performed in duplicate on the Rotor-Gene 6000
(Corbett Research Ltd, Cambridge, UK), and the raw data
were analysed using the comparative quantification analysis
(Rotor-Gene 6000 software, Corbett Research Ltd, Cam-
bridge, UK). The specificity of all amplifications was
determined by melting curve analysis. All analyses were
processed blinded to case–control status of samples. Using
the linear regression line between measures obtained by
both the PCR-based method and the conventional terminal
restriction fragment (TRF) analysis for the same set of 32
samples, as previously described, the corresponding telo-
mere length in base pairs (bp) was calculated from the T/S
ratio measured in each subject [12].
To assess the validity of the method, variability in telomere
and SCG PCR amplification efficiency was compared
between the three studies. Values were comparable, and the
standard deviations overlapped, rendering the T/S ratios
obtained in different runs comparable. To ascertain that
inter-assay variability did not interfere with the results, T/S
ratio measurements were repeated for 32 samples from the
FH-SB group without CHD and 32 UK controls from the
HIFMECH study in two runs including samples from both
studies. LTL was longer in the FH group (9.41 kb, SD=6.20)
compared to the UK controls (8.49, SD=5.10; p=0.059) for
this sub-set of samples, as reported for the total group.
Statistical methods
Statistical analysis was performed using Stata (version 10,
StataCorp Texas). Analysis was restricted to Caucasians in
order to maintain ethnic homogeneity in the sample.
Telomere length, body mass index (BMI), triglycerides,
insulin, homocysteine, C-reactive protein and systolic blood
pressure were not normally distributed, and thus log-
transformed data were used for the analysis, and geometric
means (approximate SD) are presented in the tables. For the
same reasons, fibrinogen and apoB levels were square root
transformed. In Table 1, p values comparing cases and
controls for different parameters are from conditional
logistic regression models in HIFMECH taking account of
matching on age and centre. For the FH study, mean values
are compared by t test. Correlations were assessed using
Pearson partial correlations to allow adjustment for age and
other covariates. Because FVIIag values could not be
transformed to a normal distribution, Spearman rank
correlation was used to test the association between FVIIag
and adjusted telomere length. For the association of
telomere length with lifestyle parameters, p values were
obtained from analysis of covariance models, and the
regression estimates were used to obtain adjusted mean
values. Adjustment was made for age, centre and exercise
in HIFMECH, age in CABG and age and gender in FH.
Results
General characteristics of the study subjects
Mean LTL was successfully determined in 559 cases and
520 controls of the HIFMECH study, 413 cases of the
CABG study and 367 SB and 81 FH-RF patients. The
characteristics of these subjects are shown in Table 1, and
they did not differ significantly from that of the whole
group for any of the parameters. In both the HIFMECH and
the FH-SB studies, there were the expected significant
differences between cases and controls in risk factors such
as BMI, diastolic blood pressure, triglyceride levels, IL6
levels and fibrinogen. In HIFMECH, where plasminogen
activator inhibitor (PAI) levels were available, cases had
significantly lower PAI levels compared to the controls.
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on telomere length
We first examined the influence of environmental and life
style factors on telomere length. As shown in Fig. 1,L T L
correlated negatively with age in the HIFMECH (r=−0.07,
p=0.03), CABG (r=−0.18, p=0.0003) and FH-SB (r=
−0.16, p<0.0002) studies. No significant gender difference
was found in the CABG group (0.95 in male vs. 0.93 in
female, p=0.74), whereas in both the FH group, men had
significantly shorter telomeres than women (9.23 kb in men
vs. 9.82 kb in women, p=0.01 for the SB group and
6.93 kb in men vs. 7.57 kb in women, p=0.02 for the RF
patients). Therefore, telomere length was adjusted for age in
all further analysis and for age and gender in analysis
concerning the FH group.
Smoking and alcohol intake did not have a significant
effect on telomere length (Table 2). However, it appeared
that the less active subjects had longer telomeres in the
combined HIFMECH cohort (p=0.005). The cases in
HIFMECH had a significantly more sedentary lifestyle
than controls (p<0.0001); the level of exercise had a
significant effect on telomere length in overall population
even after adjustment for case–control status (p=0.005).
Nevertheless, no significant association between LTL and
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Fig. 1 Decrease of telomere length with age. Telomere length is
plotted as loge T/S ratio. r values were −0.18 (p=0.0003), −0.07 (p=
0.03) and −0.16 (p<0.0002), −0.35 (p=0.0002) for CABG, HIF-
MECH, FH-SB and FH-RH, respectively
Table 1 Characteristics of study subjects
HIFMECH CABG FH-SB FH-RF
Controls Cases p value −CHD +CHD p value −CHD +CHD
Number (% women) 559 (0) 520 (0) – 341 (20.8) 222 (56.8) 145 (33.8) <0.0001 77 (61.3) 17 (47.1) 0.28
Age (years) 51.5 (5.5) 51.9 (5.4) – 64.9 (92.2) 44.3 (13.4) 56.1 (10.3) <0.0001 51.9 (14.3) 58.7 (14.0) 0.08
BMI (kg/m
2) 26.1 (3.2) 27.1 (3.3) 0.001 28.2 (4.5) 23.8 (4.0) 25.1 (3.4) 0.005
SBP (mmHg) 127.8 (14.4) 127.7 (16.9) 0.75 123.7 (15.6) 130.6 (19.7) 0.0003
DBP (mmHg) 84.0 (8.4) 81.7 (10.2) <0.0001 77.3 (9.1) 79.3 (11.3) 0.06
Cholesterol (mmol/l) 5.52 (0.97) 5.40 (1.18) 0.06 4.71 (1.03) 6.91 (1.30) 6.35 (1.31) <0.0001 8.76 (1.50) 10.11 (2.77) 0.02
Triglyceride (mmol/l) 1.44 (0.61) 1.88 (0.77) <0.0001 1.24 (0.56) 1.46 (0.69) 0.001 1.52 (0.68) 2.16 (1.24) 0.03
LDL (mmol/l) 2.53 (0.88) 4.80 (1.28) 4.21 (1.23) <0.0001 6.34 (1.48) 7.65 (2.68) 0.05
HDL (mmol/l) 1.23 (0.35) 1.38 (0.35) 1.28 (0.36) 0.01 1.47 (0.40) 1.10 (0.29) 0.005
Insulin (mU/l) 37.8 (24.3) 49.3 (34.5) <0.0001
Glucose (mmol/l) 6.19 (2.05) 4.82 (0.59) 5.07 (0.59) 0.0001
Homocysteine (μmol/l) 8.27 (2.59) 8.55 (3.36) 0.03 10.54 (3.45) 11.57 (3.20) 0.005
CRP (mg/l) 1.23 (1.40) 2.22 (2.55) <0.0001 2.29 (2.77) 1.16 (1.34) 1.42 (1.59) 0.10
IL-6 (pg/ml) 1.24 (0.78) 1.97 (1.33) <0.0001 4.55 (3.12) 1.58 (1.14) 2.18 (1.34) <0.0001
Fibrinogen (g/L) 3.40 (0.69) 3.71 (0.92) <0.0001 3.64 (0.77) 2.76 (0.78) 3.11 (0.99) 0.0002
FVIIag (IU/ml) 1.17 (0.39) 1.12 (0.45) 0.14
PAI (citrate; AU/ml) 35.1 (21.9) 40.4 (24.3) 0.001 8.27 (6.1) 10.62 (7.86) 0.002
PAI (stabilite; AU/ml) 23.4 (18.5) 32.9 (24.8) <0.0001
Unadjusted telomere
length (kbp)
8.04 (4.51) 7.90 (4.05) 0.34 6.85 (4.23) 9.82 (4.88) 9.04 (4.74) 0.001 7.53 (4.05) 6.70 (3.45) 0.03
Unadjusted geometric means (standard deviation) are presented
BMI, triglyceride, insulin, homocysteine, CRP, SBP and homocysteine were log-transformed for tests; fibrinogen level is square root transformed
p values for HIFMECH are from conditional logistic regression model taking account of the matching on age and centre
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LDL low-density lipoprotein, HDL high-density lipoprotein,
CRP C-reactive protein, IL-6 interleukin-6, FVIIag factor VII antigen, PAI plasminogen activator inhibitor
788 J Mol Med (2010) 88:785–794fitness level was found in HIFMECH when cases and
controls were examined separately. In order to avoid any
possible confounding effect in the rest of the analysis in
HIFMECH, telomere length was adjusted for exercise level.
Age, exercise and case–control status-adjusted telomeres
were significantly longer in subjects from the South
compared to the North of Europe (8.27 kb, SD=4.14
vs.7.99 kb, SD=4.51, p=0.02; Fig. 2), and the difference
corresponds to approximately 280 bp. Scatter plots of the
distribution of the telomere length in North and South are
shown in web appendix 1 of the Electronic supplementary
material. All further analysis in HIFMECH was also
adjusted for region.
Case–control status and telomere length
HIFMECH
Age-, region- and exercise-adjusted LTL was significantly
shorter in CHD cases (7.85 kb, SD=4.01) compared to
controls (8.04 kb, SD=4.46; Fig. 3). The difference
corresponds to approximately 190 bp.
CABG
LTL was significantly shorter in CABG cases (6.89 kb,
SD=4.14) compared to HIFMECH UK controls (7.53 kb,
SD=5.29; p=0.007) or to all HIFMECH controls (7.72 kb,
SD=3.78; p<0.0001) (Fig. 3). After 6 years of follow-up in
the CABG study, 40 deaths were recorded. Interestingly,
subjects who died in these 6 years had marginally shorter
telomere (6.66 kb, SD=4.01) compared to those who
survived (6.94 kb, SD=4.14; p=0.28).
FH patients
Amongst the SB patients, age- and gender-adjusted LTL
was borderline significantly shorter in those with CHD
(9 kb, SD=4.74) compared to those without CHD (9.46 kb,
SD=4.74; p=0.09; Fig. 3). Additionally, telomere length
was compared between 222 FH-SB patients without CHD
and 70 UK controls from the HIFMECH study. Adjusted to
males aged 49 years, LTL was longer in the FH patients
(9.46 kb, SD=4.74) compared to controls (7.67 kb, SD=
5.33; p<0.0001).
Table 2 Lifestyle parameters and telomere length
HIFMECH CABG FH
LTL p value LTL p value LTL p value
Smoking Current 1.17 (0.35) 255 0.42 0.90 (0.36) 54 0.44 1.54 (0.43) 53 0.44
Ex 1.14 (0.36) 518 0.96 (0.34) 212 1.46 (0.50)125
Never 1.17 (0.41) 306 0.94 (0.34) 75 1.44 (0.47) 189
Alcohol Yes 1.16 (0.39) 782 0.74
Ex 1.12 (0.34) 61
Never 1.17 (0.30) 226
Exercise Sedentary 1.17 (0.33) 399 0.005
Moderate active 1.19 (0.41) 399
Active 1.09 (0.36) 183
Fit 1.10 (0.34) 93
Mean (standard deviation) and number of people in the category are presented. HIFMECH results were adjusted for age and centre. CABG results
were age adjusted and FH results age and gender adjusted
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Fig. 2 Comparison of leukocyte
telomere length (kilobytes) be-
tween North and South in HIF-
MECH study. Geometric mean
of age, exercise and status ad-
justed telomere length (in kilo-
bytes) and confidence interval
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was borderline significantly shorter in those with CHD
(6.84 kb, SD=3.4) compared to those without (7.53 kb, SD=
4; p=0.066). However, the difference was not significant when
adjusted for age and gender (p=0.15). When combining both
cohorts (FH-SB and FH-RF), LTL was shorter in those with
CHD (overall 8.68 kb, SD 4.65) compared to the non-CHD
subjects (9.23 kb, SD 4.83; p=0.012), confirming the
borderline significantassociationfoundwiththe firstFHgroup.
LTL was compared between the FH-RF patients without
CHD to the UK HIFMECH controls. LTL was not longer in
the FH patients (7.53 kb, SD=4) compared to controls
(7.67 kb, SD=5.33; p=0.93), suggesting that the difference
found previously in the FH-SB group may be a chance effect.
Risk factors, medication and telomere length
Overall, the association between CHD and shorter LTL is
very consistent for the four studies presented here. Given
this consistent association, the correlation between telomere
length and classical CHD risk factors was examined. As
shown in Table 3, in the FH-SB subjects, BMI, triglyceride
and fibrinogen levels correlated positively with telomere
length (r=0.26, p<0.0001, r=0.11, p=0.03 and r=0.11, p=
0.04, respectively) but these effects were not consistent
across studies. In HIFMECH cases, insulin level correlated
negatively with telomere length (r=−0.15, p=0.005),
Insulin levels were not available in the CABG and FH
cohorts. Glucose level displayed positive correlation with
telomere length in the FH-SB patients (r=0.14, p=0.006)
but not in the CABG group (r=−0.06, p=0.38). No
association was found between telomere length and
diabetes, hypertension or hyperlipidaemia in either the
HIFMECH (cases and controls tested separately) and the
CABG cohorts. A strong correlation was observed between
LTL and IL-6 levels in CABG patients (r=0.23, p<0.0001).
Scatter plots for the three stronger associations (glucose in
FH, IL-6 in CABG and insulin in HIFMECH cases) are
available as web appendix 2 to 4 of the Electronic
supplementary material. Mean PAI levels were significantly
lower in HIFMECH cases compared to controls, and a
weak negative correlation was found between telomere
length and stability PAI level (r=−0.08, p=0.02 when cases
and controls are combined).
Finally, the effect of statin treatment on telomere length
in FH patients was assessed. Figure 4 presents the inverse
correlation observed between the duration of statin use and
telomere length (r=−0.20, p=0.0004, N=302) in the FH-
SB group. No correlation was found in the second group of
FH-RF patients (r=0.02, p=0.85, N=66).
Discussion
In this study, we report shorter LTL in premature MI male
patients, in CHD patients undergoing a first elective CABG
and in FH patients with early CHD compared to those
without CHD. Using the correlation between telomere
length and age, the decline in telomere length is approxi-
mately 14 bp per year in HIFMECH and 34 bp per year in
FH studies. From these values, the difference in mean LTL
between CHD cases and controls (190 bp in HIFMECH
and 460 bp in FH) corresponds to a biological age gap of
more than 10 years. MI cases had LTL of healthy subjects
who were roughly 15 years older in HIFMECH, and in the
FH-SB group, CHD cases had telomeres of 17 years older
FH controls. This is in accordance with Brouilette et al. [11]
who found that premature MI cases have on average a
biological age equivalent to 11.3 years older than controls.
Our data, coupled with those of others [11, 21–24], strongly
suggest that shorter telomere length is a risk factor for CHD
and MI. A recent study by Wilson et al. [25] showed that
telomere length in vascular wall cells from abdominal
aortas of patients undergoing elective open repair, as well
as from normal aortas of cadaveric donors strongly
correlates with LTL of the same subjects (r=0.62, p=
0.001). Therefore, overall, the data suggest that MI and
CHD are linked to excessive ageing of the vascular wall,
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790 J Mol Med (2010) 88:785–794which is reflected by shorter telomeres in this tissue, and
that LTL can serve as a marker of this process. This raises
the possibility, as discussed by others [26], that telomere
length could be used to identify individual patients who
may be at particularly high risk of CHD, and who may
benefit from earlier or more intensive statin treatment.
However, because telomere length is highly variable at
birth and between different ethnicity [8, 9], it is not
p o s s i b l et oe s t a b l i s hac u t - o f fv a l u ei nt e l o m e r el e n g t ht o
distinguish patients who may benefit from early use of
medication. Although chronological age is a strong
predictor of CHD risk, further research is required to
establish the additional relevance of “biological age” in
CHD prediction, and to determine absolute values for
individual telomere length.
In the HIFMECH sample, telomeres were significantly
longer in the South (San Giovanni Rotondo and Marseille)
compared to the North of Europe (Stockholm and London).
A gradient in CHD risk has been repeatedly reported across
Europe (e.g. [27]) and telomere length differences in young
healthy male students from middle Europe and UK [12]. In
EARSII, telomere length was longer in students from the
Middle of Europe (10.28 kb) compared to the UK
(9.64 kb), the Baltic (7.95 kb) and the South (7.62 kb).
Comparison between the HIFMECH samples presented
here and the EARSII sample is difficult considering the
broad definition of the geographical regions in these two
studies. Nevertheless, the region considered as South in
HIFMECH lies between the geographical regions consid-
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Fig. 4 Correlation between telomere length and duration of statin use
in FH patients. Telomere length is plotted as loge T/S ratio. r values
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Table 3 Partial Pearson correlation coefficients of telomere length with classical risk factors
HIFMECH CABG FH
Controls Cases Cases Cases
rp value rp value rp value rp value
BMI (kg/m
2) −0.07 0.09 −0.07 0.13 0.03 0.63 0.26 <0.0001
SBP (mmHg) −0.01 0.76 0.04 0.35 −0.06 0.29
DBP (mmHg) −0.02 0.60 −0.02 0.73 −0.08 0.13
Cholesterol (mmol/l) −0.02 0.61 −0.03 0.56 −0.01 0.86 −0.03 0.54
Triglyceride (mmol/l) −0.004 0.93 −0.07 0.15 0.11 0.03
LDL (mmol/l) −0.02 0.8 −0.06 0.28
HDL (mmol/l) −0.02 0.8 −0.03 0.54
Insulin (mU/l) −0.008 0.87 −0.15 0.005
Glucose (mmol/l) −0.06 0.38 0.14 0.006
Homocysteine (μmol/l) −0.03 0.53 −0.06 0.16 0.02 0.77
CRP (mg/l) −0.01 0.77 0.003 0.95 0.12 0.03 0.05 0.34
IL-6 (pg/ml) 0.02 0.75 −0.06 0.25 0.23 <0.0001 0.07 0.16
Fibrinogen (g/L) 0.002 0.97 −0.06 0.22 0.07 0.22 0.11 0.04
FVIIag (IU/ml) −0.04 0.37 −0.07 0.11
PAI (citrate) (AU/ml) −0.06 0.19 −0.06 0.17 0.02 0.74
PAI (stabilite) (AU/ml) −0.09 0.06 −0.08 0.09
Partial Pearson correlation coefficients r was adjusted for age, centre and exercise in HIFMECH, age in CABG and age and gender in FH and
further adjusted for case–control status when cases and controls are pooled
BMI, triglyceride, insulin, homocysteine, CRP, SBP and homocysteine were log-transformed for tests; fibrinogen level is square root transformed
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LDL low-density lipoprotein, HDL high-density lipoprotein,
CRP C-reactive protein, IL-6 interleukin-6, FVIIag factor VII antigen, PAI plasminogen activator inhibitor
J Mol Med (2010) 88:785–794 791ered as Middle and South in EARSII [12], and the data
appear broadly consistent. Although there appears to be
some agreement between the well-known gradient of
C H Dr i s ka c r o s sE u r o p ew i t ht h a ts e e ni nt e l o m e r e
length, more data on telomere length in the different
European countries is needed to confirm this.
Lifestyle is well known to be one of the stronger
predictors of CHD risk, and a modest effect of lifestyle on
telomere length has been previously reported. Smoking has
been associated with shorter telomeres in controls [28]a s
well as in lean and obese women [29], while greater
physical activity in leisure time has been associated with
longer telomeres in healthy twins [30]. In contrast to many
published reports, in the four studies presented here, no
consistent correlation was found between telomere length
and several examined cardiovascular risk factors such as
smoking habit, insulin and glucose levels, although in
individual studies, some significant associations were
observed. However, in any particular study, the absence
of a significant correlation can be due to lack of power
resulting from the relatively small sample size. Thus, we
cannot confirm or refute these reported associations,
although in general, they appear to be relatively weak.
In the present study, exercise was associated with shorter
telomeres in the HIFMECH study, an observation which is
in contrast with previously published data. However, this
association was not significant when cases and controls
were analysed separately. This may suggest that the health
status of the study participants had influenced their
answers to the lifestyle questionnaire. It seems more
likely that the effect of mild exercise on telomere length,
if any, is small and therefore difficult to detect, particu-
larly when physical activity is assessed by general
questionnaires.
A significant positive association between glucose levels
and telomere length was found in the FH subjects of the
current study, and this is in accordance with the previous
finding of Salpea et al. [12] in the EARSII study (r=0.21,
p=0.0001). On the other hand, Fitzpatrick et al. [21]
reported a weak negative correlation between fasting
glucose level and telomere length (r=−0.0015, p=0.06).
For the insulin levels, a negative correlation with telomere
length was found in the HIFMECH controls, which has also
beenreportedbyAvivetal.[31] in a sample of 18–79 year-old
women, representative of the general population (r=−0.069,
p=0.023). More work is needed to clarify if any clinically
relevant association exists. In vitro work with cell cultures
being treated with various glucose concentrations may
help us understand this phenomenon. Nevertheless,
many studies have shown that subjects with impaired
glucose tolerance and type II diabetes have shorter
telomeres than controls [13–15]. The association between
the presence of diabetes and telomere length was tested in
both the HIFMECH and the CABG cohorts, but no
significant association was detected. This could possibly
be due to the size of the cohort and/or the fact that severity
and the complications of the CHD in the cases are
masking the effect of diabetes.
This study is the first to evaluate LTL in FH patients.
Two independent cohorts of patients were studied. The
patients suffering from CHD had roughly 550-bp shorter
telomeres than FH patients without CHD. This is in
accordance with the results reported for classical polygenic
CHD and extends the observation of shorter leukocyte
telomeres to this monogenic form of CHD. Interestingly, in
the first cohort, the FH patients without CHD had
approximately 1,780-bp longer telomeres than healthy
controls after adjustment for age and gender. However,
the difference was not confirmed in the second group of
patients, and the observation of longer telomeres in FH-SB
patients free of CHD may be by chance. It is worth
mentioning that the mean age in the SB FH patients without
CHD was 7 years younger than both the FH-RF patients
and the HIFMECH controls. Since telomere length was
adjusted for age, this age difference should not be the cause
for this difference. However, age may be related to the
health status of the patients and/or the medication they have
received, which could influence their telomere length.
Additionally, the two FH groups were recruited in different
centres, which may have caused heterogeneity in the
patients' characteristics. Another explanation could be that
the SB FH patients without CHD being recruited in this
study are the “survivors”, and those with shorter telomere
length had died earlier. It will be of great interest to
evaluate telomere length in more FH patients and if the
longer telomeres in FH compared to controls are replicated,
then the underlying mechanism should be investigated.
No correlation between total cholesterol levels and
telomere length was found in FH patients or the two other
cohorts studied, which is in line with previously published
data from our laboratory [12] and from others [11]. Satoh et
al. [32] showed recently that in a culture of endothelial
progenitor cells (EPC) subject to oxidative stress (tert-butyl
hydroperoxide or L-buthionine-[S, R]-sulphoximine), inten-
sive lipid lowering treatment with atorvastatin led to the
prevention of EPC telomere shortening. Mahmoudi et al.
[33] showed that atorvastatin treatment reduced telomere
shortening in vascular smooth muscle cells cultured with
tert-butylhydroperoxide, a free radical-generating agent.
Considering the protective effect of statins against telomere
shortening as shown with these experiments, we reasoned
that the longer telomere length in FH-SB patients free of
CHD compared to healthy subjects could be a consequence
of the prolonged statin treatment that these patients have
received. While a proof of this hypothesis would require the
availability of follow-up measurements of telomere length
792 J Mol Med (2010) 88:785–794in subjects under statin or not, the observed significant
negative correlation between telomere length and duration
of statin use in the FH-SB group renders this explanation
less likely. Interestingly, in the prospective WOSCOPS
study, Brouilette et al. [22] reported that pravastatin
treatment had the greatest benefit for CHD prevention in
people in the lowest tertile of telomere length at recruitment
compared to those with longest telomeres. Brouilette et al.
suggest that the mechanism of this effect may be due to a
statin-induced increase in expression of the important
telomere capping protein TRF2, which has been reported
in cultures of EPC treated with statin [34]. In this case,
telomere structure would be stabilised and preventing this
way telomere shortening. The direct relevance of this to
patients has yet to be confirmed.
It is puzzling that a positive correlation with BMI was
found in FH patients, because telomere length is usually
negatively correlated with BMI as it was observed for
HIFMECH controls and has been shown in other studies
[12]. It is relevant that in the FH-SB group, the three risk
factors that were significantly correlated with telomere
length were also correlated with each other (BMI and
triglyceride, r=0.26, p<0.001; triglyceride and glucose, r=
0.20, p<0.001; BMI and glucose, r=0.20, p<0.001),
suggesting that some of the associations observed with
telomere length may result from this reason.
In the CABG patients, a weak positive (r=0.23)
correlation between pre-operative IL6 levels and telomere
length was found, but this association did not persist post-
operatively and also was not replicated in the FH group.
Other studies [21, 35] have reported a negative correlation
between telomere length and IL6 levels (r=−0.408, p=
0.08, r=−0.17, p=0.02) in the Cardiovascular Health Study
cohort, an observational cohort designed to investigate risk
factors for cardiovascular disease in the elderly and
multiple myeloma, respectively. The unexpected correlation
with IL6 observed in CABG patients before the operation
may be due to the condition, the medication and/or changes
in the patients' treatment before the operation or to chance.
In conclusion, it is now strongly confirmed that telomere
shortening is a marker of normal ageing and CHD along with
its complications as MI. Our data in four different case–
control studies support this concept and include the first data
indicating that FH patients with CHD have shorter telomeres
than FH patients without CHD. Our analysis on the
association of CHD risk factors and telomere length confirms
the previously observed association with geographical local-
ization of the studied subjects and with glucose levels.
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